Timothy A. Gottschalk

Timothy A. Gottschalk

Auto-generated profile, based on publicly available information

Timothy A. Gottschalk

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
TGTimothy A. Gottschalk
Timothy A. Gottschalk
ETEvelyn Tsantikos
Evelyn Tsantikos
MHMargaret L Hibbs
Margaret L Hibbs
Systemic Lupus Erythematosus (SLE, lupus) is a highly complex and heterogeneous autoimmune disease that most often afflicts women in their child-bearing years. It is characterized by circulating self-reactive antibodies that deposit in tissues including skin, kidneys and brain, and the ensuing inflammatory response can lead to irreparable tissue damage. Over many years, clinical trials in SLE have focused on agents that control B and T lymphocyte activation, and, with the single exception of an agent known as Belimumab which targets the B cell survival factor BAFF, they have been disappointing. At present, standard therapy for SLE with mild disease is the agent hydroxychloroquine. During disease flares, steroids are often used, while the more severe manifestations with major organ involvement warrant potent, broad-spectrum immuno-suppression with cyclophosphamide or mycophenolate. Current treatments have severe and dose-limiting toxicities and thus a more specific therapy targeting a causative factor or signaling pathway would be greatly beneficial in SLE treatment. Moreover, the ability to control inflammation alongside B cell activation may be a superior approach for disease control. There has been a recent focus on the innate immune system and associated inflammation, which has uncovered key players in driving the pathogenesis of SLE. Delineating some of these intricate inflammatory mechanisms has been possible with studies using spontaneous mouse mutants and genetically engineered mice. These strains, to varying degrees, exhibit hallmarks of the human disease and therefore have been utilized to model human SLE and to test new drugs. Developing a better understanding of the initiation and perpetuation of disease in SLE may uncover suitable novel targets for therapeutic intervention. Here we discuss the involvement of inflammation in SLE disease pathogenesis, with a focus on several key proinflammatory cytokines and myeloid growth factors, and review the known outcomes or the potential for targeting these factors in SLE.

1 September 2020 in The American Journal of Pathology
Verified
Journal Article
Closed access
LWLakshanie C. Wickramasinghe
Lakshanie C. Wickramasinghe
MLMaverick Lau
Maverick Lau
DDDevy Deliyanti
Devy Deliyanti
TGTimothy A. Gottschalk
Timothy A. Gottschalk
PWPeter van Wijngaarden
Peter van Wijngaarden
MHMargaret L Hibbs
Margaret L Hibbs

12 November 2024 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
HTHazel Tye
Hazel Tye
SCStephanie A Conos
Stephanie A Conos
TDTirta M Djajawi
Tirta M Djajawi
TGTimothy A Gottschalk
Timothy A Gottschalk
NANasteho Abdoulkader
Nasteho Abdoulkader
KLKate E. Lawlor
Kate E. Lawlor
Cell death frequently occurs in the pathogenesis of obesity and metabolic dysfunction–associated fatty liver disease (MAFLD). However, the exact contribution of core cell death machinery to disease manifestations remains ill-defined. Here, we show via the direct comparison of mice genetically deficient in the essential necroptotic regulators, receptor-interacting protein kinase-3 (RIPK3) and mixed lineage kinase domain–like (MLKL), as well as mice lacking apoptotic caspase-8 in myeloid cells combined with RIPK3 loss, that RIPK3/caspase-8 signaling regulates macrophage inflammatory responses and drives adipose tissue inflammation and MAFLD upon high-fat diet feeding. In contrast, MLKL, divergent to RIPK3, contributes to both obesity and MAFLD in a manner largely independent of inflammation. We also uncover that MLKL regulates the expression of molecules involved in lipid uptake, transport, and metabolism, and congruent with this, we discover a shift in the hepatic lipidome upon MLKL deletion. Collectively, these findings highlight MLKL as an attractive therapeutic target to combat the growing obesity pandemic and metabolic disease.

7 May 2021 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
PDF file
TGTimothy A. Gottschalk
Timothy A. Gottschalk
FVFabien B. Vincent
Fabien B. Vincent
AHAlberta Y. Hoi
Alberta Y. Hoi
MHMargaret L Hibbs
Margaret L Hibbs
Systemic lupus erythematosus (lupus) is an autoimmune disease characterized by autoantibodies that form immune complexes with self‐antigens, which deposit in various tissues, leading to inflammation and disease. The etiology of disease is complex and still not completely elucidated. Dysregulated inflammation is an important disease feature, and the mainstay of lupus treatment still utilizes nonspecific anti‐inflammatory drugs. Granulocyte colony‐stimulating factor (G‐CSF) is a growth, survival, and activation factor for neutrophils and a mobilizer of hematopoietic stem cells, both of which underlie inflammatory responses in lupus. To determine whether G‐CSF has a causal role in lupus, we genetically deleted G‐CSF from Lyn‐deficient mice, an experimental model of lupus nephritis. Lyn−/−G‐CSF−/− mice displayed many of the inflammatory features of Lyn‐deficient mice; however, they had reduced bone marrow and tissue neutrophils, consistent with G‐CSF's role in neutrophil development. Unexpectedly, in comparison to aged Lyn‐deficient mice, matched Lyn−/−G‐CSF− /− mice maintained neutrophil hyperactivation and exhibited exacerbated numbers of effector memory T cells, augmented autoantibody titers, and worsened lupus nephritis. In humans, serum G‐CSF levels were not elevated in patients with lupus or with active renal disease. Thus, these studies suggest that G‐CSF is not pathogenic in lupus, and therefore G‐CSF blockade is an unsuitable therapeutic avenue.

17 October 2023 in EMBO Reports
Verified
Journal Article
Open access
MSMary Speir
Mary Speir
HTHazel Tye
Hazel Tye
TGTimothy A Gottschalk
Timothy A Gottschalk
DSDaniel S Simpson
Daniel S Simpson
TDTirta M Djajawi
Tirta M Djajawi
KLKate E. Lawlor
Kate E. Lawlor
Programmed cell death pathways play an important role in innate immune responses to infection. Activation of intrinsic apoptosis promotes infected cell clearance; however, comparatively little is known about how this mode of cell death is regulated during infections and whether it can induce inflammation. Here, we identify that the pro‐survival BCL‐2 family member, A1, controls activation of the essential intrinsic apoptotic effectors BAX/BAK in macrophages and monocytes following bacterial lipopolysaccharide (LPS) sensing. We show that, due to its tight transcriptional and post‐translational regulation, A1 acts as a molecular rheostat to regulate BAX/BAK‐dependent apoptosis and the subsequent NLRP3 inflammasome‐dependent and inflammasome‐independent maturation of the inflammatory cytokine IL‐1β. Furthermore, induction of A1 expression in inflammatory monocytes limits cell death modalities and IL‐1β activation triggered by Neisseria gonorrhoeae ‐derived outer membrane vesicles (NOMVs). Consequently, A1‐deficient mice exhibit heightened IL‐1β production in response to NOMV injection. These findings reveal that bacteria can induce A1 expression to delay myeloid cell death and inflammatory responses, which has implications for the development of host‐directed antimicrobial therapeutics.

10 June 2026 in Nature Communications
Verified
Journal Article
Open access
HWHarshini Weerasinghe
Harshini Weerasinghe
OTOrawan Tulyaprawat
Orawan Tulyaprawat
HSHelen Stölting
Helen Stölting
JSJohannes Sonnberger
Johannes Sonnberger
BMByron Mobbs
Byron Mobbs
ATAna Traven
Ana Traven
Pathogens compete for glucose with macrophages, which disrupts host glycolysis, modulates antimicrobial responses and causes macrophage death. We show that glucose starvation induced by major fungal pathogens Candida albicans and Candida auris causes macrophage lysis by activating NINJ1, the executioner of membrane rupture during cell death. In glucose-starved macrophages, NINJ1 ruptures membranes independently of known cell death programs. Consistently, NINJ1 is the dominant effector of fungal-induced macrophage damage amongst host cell death factors. Supplementation of the amino acid alanine rescues glucose-starved macrophages better than glucose, and it does so by inhibiting NINJ1 oligomerization. Moreover, C. albicans infection disrupts amino acid metabolism in mice and reduces serum alanine. Finally, NINJ1-mediated membrane rupture enables C. albicans egress from macrophages together with the toxin candidalysin. We establish the mechanism of glucose starvation-induced macrophage damage by NINJ1, and demonstrate the roles of NINJ1 and alanine in immune responses to Candida and fungal escape.